Kodiak Sciences is trading 4.15% down at $89.11, as investors weigh potential dilution following an October 20 stock-sale filing.
- The automatic shelf filing and agreement allow sales of up to $350 million of common stock through J.P. Morgan.
- The program creates potential dilution but does not require the company to sell shares.
- The biotech sector was recently strong, and no separate October 21 company announcement was identified.